兩家獨立企業由此誕生
生命科學與診斷 & 分析和企業服務

×
×

兩家獨立企業由此誕生

  • 生命科學與診斷業務

    專注於生命科學和診斷業務的高增長型公司,推動科學家和醫療衛生專業人士的研究、發現和檢測,助力打造更健康的世界

  • 分析和企業服務業務

    我們專注於提供全方位的分析和企業服務解決方案,包括領先的OneSource實驗室服務,加速您的科學研究進程

Development of an AlphaLISA Assay to Measure and Screen Inhibitors of the p53-MDM2 Interaction | 爱游戏平台注册登录 - 爱游戏登录网,爱游戏平台注册登录
爱游戏平台注册登录

Technical Note

Development of an AlphaLISA Assay to Measure and Screen Inhibitors of the p53-MDM2 Interaction

Introduction

Binding events between biomolecules are important components of biological processes and a number of these biomolecular interactions have been targeted for the development of novel therapeutic drugs. p53 is a transcription factor and tumor suppressor protein that is activated in response to cellular stress, and MDM2 was identified as a negative regulator that binds to p53 and tags it for ubiquitination and subsequent degradation.

The p53-MDM2 protein-protein interaction has been an excellent target for therapeutic drugs and therefore makes a good model system for developing an AlphaLISA assay to screen for inhibitors of the interaction. In this technical note, we show how to develop an assay to screen for inhibitors and how to measure a dissociation constant for moderate binding protein-protein interaction using AlphaLISA®.

Baidu
map